Xichun C. Hu

No. 270, Dong An Road
Shanghai, 200032, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 237 publications

Prominin 2 promotes the progression of breast cancer by inhibiting ferroptosis via MAPK signaling.

Prominin 2 promotes the progression of breast cancer by inhibiting ferroptosis via MAPK signaling.

Journal: Journal of translational internal medicine

Published: August 27, 2026

Clinical impact of 18F-FES PET/CT-detected ER-positive conversion in metastatic breast cancer with ER-negative primary tumors.

Clinical impact of 18F-FES PET/CT-detected ER-positive conversion in metastatic breast cancer with ER-negative primary tumors.

Journal: European journal of nuclear medicine and molecular imaging

Published: May 06, 2026

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).

Phase II Clinical Study of Adebrelimab and Bevacizumab Combined With Cisplatin/Carboplatin in Patients With Triple-Negative Breast Cancer With Brain Metastases (ABC Study).

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: March 04, 2026

Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial.

Anti-PD-1 plus nab-paclitaxel and bevacizumab for second-line treatment of cancer of unknown primary (Fudan CUP-002): a phase II trial.

Journal: Nature communications

Published: January 04, 2026

HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

HER2CLIMB-05: A Phase III Study of Tucatinib Versus Placebo in Combination With Trastuzumab and Pertuzumab as First-Line Maintenance Therapy for HER2+ Metastatic Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: December 10, 2025

Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.

Exploratory Analysis of PTEN Deficiency by Immunohistochemistry from the Phase III CAPItello-291 Trial.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: December 08, 2025

First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC.

First-in-human phase 1/2a study of T3011, an oncolytic HSV expressing IL-12 and PD-1 antibody, administered via intratumoral (IT) injection as monotherapy in advanced solid tumors, including recurrent or metastatic HNSCC.

Journal: BMC medicine

Published: November 28, 2025

Multimodal parameters for the diagnosis of putative primaries of cancer of unknown primary.

Multimodal parameters for the diagnosis of putative primaries of cancer of unknown primary.

Journal: iScience

Published: October 16, 2025

Complex I protein NDUFB9 is a metabolic vulnerability in triple negative breast cancer brain metastases.

Complex I protein NDUFB9 is a metabolic vulnerability in triple negative breast cancer brain metastases.

Journal: Nature communications

Published: October 03, 2025

Entrectinib in Asian patients with ROS1 fusion-positive non-small cell lung cancer: updated efficacy and safety analysis.

Entrectinib in Asian patients with ROS1 fusion-positive non-small cell lung cancer: updated efficacy and safety analysis.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 12, 2025

A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer.

A phase II randomized trial of gemcitabine plus cisplatin (GP) versus gemcitabine plus carboplatin (GC) as the first-line treatment of patients with metastatic triple-negative breast cancer.

Journal: ESMO open

Published: August 27, 2025

OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer.

OPTIMAL: a multinational phase III study of oral paclitaxel (DHP107) versus intravenous weekly paclitaxel in HER2-negative recurrent or metastatic breast cancer.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 26, 2025

Showing 1-12 of 237

Last Updated: 09/26/2026